. . "2" . "RIV/00216208:11130/14:10294047" . . . "I" . "11130" . "Aktuality v l\u00E9\u010Db\u011B inhibitory dipeptidyl peptid\u00E1zy 4"@cs . "Aktuality v l\u00E9\u010Db\u011B inhibitory dipeptidyl peptid\u00E1zy 4" . . "therapy; DPP-4"@en . "Posledn\u00EDch dvan\u00E1ct m\u011Bs\u00EDc\u016F p\u0159ineslo \u0159adu nov\u00FDch informac\u00ED o p\u016Fsoben\u00ED inhibitor\u016F dipeptidyl peptid\u00E1zy 4 (DPP-4) p\u0159edev\u0161\u00EDm v oblasti bezpe\u010Dnosti a n\u00E1sledn\u011B i anal\u00FDzy v\u00FDsledk\u016F prvn\u00EDch studi\u00ED hodnot\u00EDc\u00EDch kardiovaskul\u00E1rn\u00ED ukazatele. Dv\u011B publikace vydan\u00E9 v prvn\u00ED polovin\u011B roku 2013 obnovily kontroverze o potenci\u00E1lu inkretin\u016F stimulovat proliferaci nejen \u03B2-bun\u011Bk, ale i jin\u00FDch bun\u011B\u010Dn\u00FDch lini\u00ED ve tk\u00E1ni pankreatu. Z\u00E1v\u011Bry odvozen\u00E9 z v\u00FDsledk\u016F t\u011Bchto prac\u00ED byly ov\u0161em p\u0159ijaty se zna\u010Dn\u00FDmi v\u00FDhradami kv\u016Fli pom\u011Brn\u011B z\u00E1va\u017En\u00FDm technick\u00FDm a metodologick\u00FDm nedostatk\u016Fm proveden\u00FDch v\u00FDzkum\u016F. Na z\u00E1klad\u011B posouzen\u00ED \u0159ady zdroj\u016F vydaly FDA a EMA v \u00FAnoru 2014 sv\u00E9 stanovisko, \u017Ee dohady o p\u0159\u00ED\u010Dinn\u00E9 souvislosti mezi l\u00E9\u010Divy odvozen\u00FDmi od inkretin\u016F a pankreatitidou \u010Di karcinomem pankreatu neodpov\u00EDdaj\u00ED sou\u010Dasn\u00FDm v\u011Bdeck\u00FDm dat\u016Fm. Do doby, ne\u017E budou k dispozici dal\u0161\u00ED informace, pova\u017Euj\u00ED tyto autority pankreatitidu jen za ur\u010Dit\u00E9 riziko, kter\u00E9 m\u016F\u017Ee b\u00FDt spojeno s touto formou l\u00E9\u010Dby. Prvn\u00ED ze s\u00E9rie studi\u00ED s inhibitory DPP-4 specificky zam\u011B\u0159en\u00FDch na p\u016Fsoben\u00ED t\u011Bchto l\u00E9\u010Div na kardiovaskul\u00E1rn\u00ED ukazatele (SAVOR, EXAMINE) nazna\u010Dily neutr\u00E1ln\u00ED vliv zkouman\u00E9ho saxagliptinu a alogliptinu na kardiovaskul\u00E1rn\u00ED syst\u00E9m. Vysv\u011Btlen\u00ED, pro\u010D se potenci\u00E1ln\u00ED pozitivn\u00ED \u00FA\u010Dinky inhibitor\u016F DPP-4 neprom\u00EDtly do sn\u00ED\u017Een\u00ED \u010Detnosti kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod, m\u00E1 jist\u011B dv\u011B roviny. Prvn\u00ED souvis\u00ED s kr\u00E1tk\u00FDm \u010Dasov\u00FDm horizontem obou studi\u00ED (\u0159\u00E1dov\u011B 2-3 roky), p\u0159i n\u011Bm\u017E nem\u016F\u017Ee doj\u00EDt p\u0159i pou\u017Eit\u00ED l\u00E9\u010Div ovliv\u0148uj\u00EDc\u00EDch prim\u00E1rn\u011B glykovan\u00FD hemoglobin k z\u00E1sadn\u00EDm struktur\u00E1ln\u00EDm zm\u011Bn\u00E1m na velk\u00FDch c\u00E9v\u00E1ch. Druhou rovinou jsou prozat\u00EDm nep\u0159\u00EDli\u0161 zn\u00E1m\u00E9 \u00FA\u010Dinky inhibice DPP-4 na funkce endotelu, dal\u0161\u00ED funkce c\u00E9vn\u00ED st\u011Bny \u010Di p\u016Fsoben\u00ED v r\u016Fzn\u00FDch tk\u00E1n\u00EDch myokardu. V\u00FDsledky dal\u0161\u00ED studie (VIVIDD) uk\u00E1zaly, \u017Ee o kardi\u00E1ln\u00EDch \u00FA\u010Dinc\u00EDch inhibitor\u016F DPP-4 u osob se srde\u010Dn\u00EDm selh\u00E1n\u00EDm v\u00EDme v sou\u010Dasn\u00E9 dob\u011B jen velmi m\u00E1lo, aby bylo mo\u017En\u00E9 prov\u00E9st seri\u00F3zn\u00ED z\u00E1v\u011Bry. Bude tak nezbytn\u00E9 vy\u010Dkat na v\u00FDsledky dal\u0161\u00EDch kardiovaskul\u00E1rn\u00EDch projekt\u016F."@cs . "CZ - \u010Cesk\u00E1 republika" . "Aktuality v l\u00E9\u010Db\u011B inhibitory dipeptidyl peptid\u00E1zy 4"@cs . . . "1"^^ . . "RIV/00216208:11130/14:10294047!RIV15-MSM-11130___" . "Update on therapy with dipeptidyl-peptidase 4 inhibitors"@en . . "The last twelve months has brought lots of new information about the effects of inhibitors of dipeptidyl peptidase 4 (DPP-4), especially in the field of security and subsequently analyzing the results of the first studies evaluating cardiovascular indicators. Two publications issued in the first half of 2013 renewed controversy about the potential of incretins stimulate the proliferation of both \u03B2-cells, but also other cell lines in tissue of the pancreas. The conclusions derived from the results of these works, however, were received with considerable reservations about relatively serious technical and methodological gaps in research projects. Based on the assessment of a number of resources granted FDA and EMA in February 2014 its opinion that the rumors of a causal link between drugs derived from incretins and pancreatitis or pancreatic cancer correspond to current scientific data. Do Pending further information is available, consider these authorities pancreatitis only certain risks that may be associated with this form of treatment. The first of a series of studies with DPP-4 inhibitors specifically focused on the effect of these drugs on cardiovascular parameters (SAVOR, examin) indicated a neutral effect of saxagliptin and examined alogliptin on the cardiovascular system. Understanding why the potential positive effects of DPP-4 inhibitors did not translate into a reduction in cardiovascular events, certainly has two levels. The first relates to the short time horizon of both studies (generally 2-3 years), which can occur when using agents primarily affecting glycated hemoglobin to major structural changes in large vessels. The second level is so far little-known effects of inhibition of DPP-4 on endothelial function, additional features of the vascular wall, or participation in various tissues infarction."@en . "6"^^ . "24" . . "1"^^ . "Honka, Marek" . . "Posledn\u00EDch dvan\u00E1ct m\u011Bs\u00EDc\u016F p\u0159ineslo \u0159adu nov\u00FDch informac\u00ED o p\u016Fsoben\u00ED inhibitor\u016F dipeptidyl peptid\u00E1zy 4 (DPP-4) p\u0159edev\u0161\u00EDm v oblasti bezpe\u010Dnosti a n\u00E1sledn\u011B i anal\u00FDzy v\u00FDsledk\u016F prvn\u00EDch studi\u00ED hodnot\u00EDc\u00EDch kardiovaskul\u00E1rn\u00ED ukazatele. Dv\u011B publikace vydan\u00E9 v prvn\u00ED polovin\u011B roku 2013 obnovily kontroverze o potenci\u00E1lu inkretin\u016F stimulovat proliferaci nejen \u03B2-bun\u011Bk, ale i jin\u00FDch bun\u011B\u010Dn\u00FDch lini\u00ED ve tk\u00E1ni pankreatu. Z\u00E1v\u011Bry odvozen\u00E9 z v\u00FDsledk\u016F t\u011Bchto prac\u00ED byly ov\u0161em p\u0159ijaty se zna\u010Dn\u00FDmi v\u00FDhradami kv\u016Fli pom\u011Brn\u011B z\u00E1va\u017En\u00FDm technick\u00FDm a metodologick\u00FDm nedostatk\u016Fm proveden\u00FDch v\u00FDzkum\u016F. Na z\u00E1klad\u011B posouzen\u00ED \u0159ady zdroj\u016F vydaly FDA a EMA v \u00FAnoru 2014 sv\u00E9 stanovisko, \u017Ee dohady o p\u0159\u00ED\u010Dinn\u00E9 souvislosti mezi l\u00E9\u010Divy odvozen\u00FDmi od inkretin\u016F a pankreatitidou \u010Di karcinomem pankreatu neodpov\u00EDdaj\u00ED sou\u010Dasn\u00FDm v\u011Bdeck\u00FDm dat\u016Fm. Do doby, ne\u017E budou k dispozici dal\u0161\u00ED informace, pova\u017Euj\u00ED tyto autority pankreatitidu jen za ur\u010Dit\u00E9 riziko, kter\u00E9 m\u016F\u017Ee b\u00FDt spojeno s touto formou l\u00E9\u010Dby. Prvn\u00ED ze s\u00E9rie studi\u00ED s inhibitory DPP-4 specificky zam\u011B\u0159en\u00FDch na p\u016Fsoben\u00ED t\u011Bchto l\u00E9\u010Div na kardiovaskul\u00E1rn\u00ED ukazatele (SAVOR, EXAMINE) nazna\u010Dily neutr\u00E1ln\u00ED vliv zkouman\u00E9ho saxagliptinu a alogliptinu na kardiovaskul\u00E1rn\u00ED syst\u00E9m. Vysv\u011Btlen\u00ED, pro\u010D se potenci\u00E1ln\u00ED pozitivn\u00ED \u00FA\u010Dinky inhibitor\u016F DPP-4 neprom\u00EDtly do sn\u00ED\u017Een\u00ED \u010Detnosti kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod, m\u00E1 jist\u011B dv\u011B roviny. Prvn\u00ED souvis\u00ED s kr\u00E1tk\u00FDm \u010Dasov\u00FDm horizontem obou studi\u00ED (\u0159\u00E1dov\u011B 2-3 roky), p\u0159i n\u011Bm\u017E nem\u016F\u017Ee doj\u00EDt p\u0159i pou\u017Eit\u00ED l\u00E9\u010Div ovliv\u0148uj\u00EDc\u00EDch prim\u00E1rn\u011B glykovan\u00FD hemoglobin k z\u00E1sadn\u00EDm struktur\u00E1ln\u00EDm zm\u011Bn\u00E1m na velk\u00FDch c\u00E9v\u00E1ch. Druhou rovinou jsou prozat\u00EDm nep\u0159\u00EDli\u0161 zn\u00E1m\u00E9 \u00FA\u010Dinky inhibice DPP-4 na funkce endotelu, dal\u0161\u00ED funkce c\u00E9vn\u00ED st\u011Bny \u010Di p\u016Fsoben\u00ED v r\u016Fzn\u00FDch tk\u00E1n\u00EDch myokardu. V\u00FDsledky dal\u0161\u00ED studie (VIVIDD) uk\u00E1zaly, \u017Ee o kardi\u00E1ln\u00EDch \u00FA\u010Dinc\u00EDch inhibitor\u016F DPP-4 u osob se srde\u010Dn\u00EDm selh\u00E1n\u00EDm v\u00EDme v sou\u010Dasn\u00E9 dob\u011B jen velmi m\u00E1lo, aby bylo mo\u017En\u00E9 prov\u00E9st seri\u00F3zn\u00ED z\u00E1v\u011Bry. Bude tak nezbytn\u00E9 vy\u010Dkat na v\u00FDsledky dal\u0161\u00EDch kardiovaskul\u00E1rn\u00EDch projekt\u016F." . "Aktuality v l\u00E9\u010Db\u011B inhibitory dipeptidyl peptid\u00E1zy 4" . "Update on therapy with dipeptidyl-peptidase 4 inhibitors"@en . "1998" . . . "Remedia" . "0862-8947" . "[878040C8569C]" .